CSF-1 Overview

CSF-1 IS CURRENTLY BEING TESTED IN TWO PHASE 3 U.S. STUDIES, NEAR-1 AND NEAR-2 FOLLOWING SUCCESSFUL PHASE 2B STUDY RESULTS.

TO FIND OUT MORE ABOUT NEAR-1 AND NEAR-2 VISIT clinicaltrials.gov: NEAR-1, NEAR-2

CSF-1 IS A NOVEL PRESBYOPIA CORRECTIVE EYE DROP

being developed to improve the quality of life for people with presbyopia by providing an alternative to reading glasses. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Our solution aims for the optimal balance between efficacy, safety and comfort with the potential to improve near vision in people with presbyopia.

CSF-1 WAS DESIGNED WITH THE PATIENT IN MIND

Clinical trial results to date have demonstrated significant improvements in near vision and a superior safety profile, supporting potential quality of life improvement in people with presbyopia. In a Phase 2b study, CSF-1 demonstrated exceptional near visual acuity with NO reduction of distance or night vision. This study also met the primary end-point, 3-line improvement in near vision (using the standard ETDRS chart).